Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On September 30, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it has delivered the first joint exhibition of CyPath ® Lung under the Company’s recently announced distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), to more than 300 physicians, healthcare prof…
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
bioAffinity Technologies, Inc. · 8-K · Filed 2026-09-30
Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
September 30, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
that it has delivered the first joint exhibition of CyPath ® Lung under the Company’s recently announced distribution
agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), to more than 300 physicians, healthcare professionals
and VA leaders at the National Association of Veterans’ Research and Education Foundations (NAVREF) Annual Conference in Arlington,
Virginia.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 News Release bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL Companies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026 bioAffinity engages GO2 for Lung Cancer network to broaden outreach to veterans at risk SAN ANTONIO, TEXAS - September 30, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, is taking significant steps toward bringing its lung cancer test to the veterans who need it. This week, bioAffinity and its federal healthcare distribution partner AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), delivered the first joint exhibition of CyPath® Lung under their new distribution agreement to more than 300 physicians, healthcare professionals and VA leaders at the National Association of Veterans’ Research and Education Foundations (NAVREF) Annual Conference in Arlington, Virginia. The companies’ nationwide federal healthcare distri…
Open exhibit ↗